Publication:
Marmosets (Callithrix jacchus) as a non-human primate model for evaluation of candidate dengue vaccines: Induction and maintenance of specific protective immunity against challenges with clinical isolates

dc.contributor.authorMeng Ling Moien_US
dc.contributor.authorYasushi Amien_US
dc.contributor.authorNor Azila Muhammad Azamien_US
dc.contributor.authorKenji Shiraien_US
dc.contributor.authorSutee Yoksanen_US
dc.contributor.authorYuriko Suzakien_US
dc.contributor.authorKazutaka Kitauraen_US
dc.contributor.authorChang Kweng Limen_US
dc.contributor.authorMasayuki Saijoen_US
dc.contributor.authorRyuji Suzukien_US
dc.contributor.authorTomohiko Takasakien_US
dc.contributor.authorIchiro Kuraneen_US
dc.contributor.otherNagasaki Universityen_US
dc.contributor.otherNational Institute of Infectious Diseasesen_US
dc.contributor.otherNational Hospital Organization, Japanen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherKanagawa Prefectural Institute of Public Healthen_US
dc.date.accessioned2018-12-21T07:50:17Z
dc.date.accessioned2019-03-14T08:03:45Z
dc.date.available2018-12-21T07:50:17Z
dc.date.available2019-03-14T08:03:45Z
dc.date.issued2017-12-01en_US
dc.description.abstract© 2017 The Authors. Dengue virus (DENV) is one of the major infectious diseases in tropical regions and approximately half of the world population is at risk of infection. Vaccines would offer an effective control measure against this disease. We previously reported on the utility of marmosets as an animal model for studying primary and secondary dengue infections. Infected marmosets consistently develop viraemia and antibody kinetics that reflect those of patients with dengue. Thus, it is important to determine the utility of marmosets as an animal model for demonstrating vaccine efficacy. In this study, marmosets were inoculated with candidate vaccine and parent strains and challenged with a clinical DENV strain. The viraemia and antibody kinetics in these marmosets were determined. Marmosets consistently develop lower viraemia with an attenuated vaccine strain. During secondary challenge, the IgM response was delayed, whereas the IgG levels rose rapidly, indicating a secondary antibody response. The neutralizing activities against the homotypic serotype were high; all marmosets were protected against viraemia following secondary inoculation. The viraemia markers and antibody responses were consistent with those of human DENV infection and vaccinees. These results demonstrate the utility of marmosets as an animal model for the study of vaccine efficacy.en_US
dc.identifier.citationJournal of General Virology. Vol.98, No.12 (2017), 2955-2967en_US
dc.identifier.doi10.1099/jgv.0.000913en_US
dc.identifier.issn14652099en_US
dc.identifier.issn00221317en_US
dc.identifier.other2-s2.0-85037721517en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/42734
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85037721517&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.titleMarmosets (Callithrix jacchus) as a non-human primate model for evaluation of candidate dengue vaccines: Induction and maintenance of specific protective immunity against challenges with clinical isolatesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85037721517&origin=inwarden_US

Files

Collections